Phase 1 proof-of-concept study of CLY-124 in Sickle Cell Disease expected in Q4 2026In vivo preclinical data assessing new compounds vs. standard of care in gold-standard, translatable myelofibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback